|

Mesna Clinical Trials

17 actively recruiting trials across 8 locations

▲ +1 trial since May 2026

Also known as: 2-Mercaptoethanesulfonate, Sodium Salt, Ausobronc, D-7093, Filesna, Mercaptoethane Sulfonate +14 more

Pipeline

Early 1: 1Phase 1: 9Phase 2: 3Phase 1/2: 3

Top Sponsors

  • St. Jude Children's Research Hospital9
  • National Cancer Institute (NCI)2
  • University of Rochester1
  • Indapta Therapeutics, INC.1
  • Dana-Farber Cancer Institute1

Indications

  • Cancer17
  • Hematologic Malignancy3
  • Neuroblastoma2
  • Acute Lymphoblastic Leukemia2
  • Myelodysplastic Syndromes2

Memphis, Tennessee9 trials

B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)

St. Jude Children's Research Hospital

Phase 1
CAR T CELL Therapy for Pediatric, Adolescent and Young Adult Patients With CD19-Positive Leukemia

St. Jude Children's Research Hospital

Phase 2
CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies

St. Jude Children's Research Hospital

Phase 1
CD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)

St Jude Children's Research Hospital

Phase 1
CD19-CD22-Bispecific Chimeric Antigen Receptor (CAR) T Cell Therapy for Pediatric Patients With Acute Lymphoblastic Leukemia

St. Jude Children's Research Hospital

Phase 1
CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma

St. Jude Children's Research Hospital

Phase 1
Evaluating Efficacy of B7-H3-CAR T Cells Administered at the End of Upfront Map Chemotherapy in Patients With Newly Diagnosed High-Risk Osteosarcoma

St. Jude Children's Research Hospital

Phase 2
Study of CD19 Allogeneic Memory T-cell Therapy for Relapsed/Refractory CD19+ Leukemia

St. Jude Children's Research Hospital

Phase 1
TCRαβ-depleted Progenitor Cell Graft With Early Memory T-cell DLI, Plus Selected Use of Blinatumomab, in naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies

St. Jude Children's Research Hospital

Phase 1

Other1 trial

Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation
Early 1

Birmingham, Alabama1 trial

A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT

Children's Hospital of Alabama

Phase 2

Duarte, California1 trial

The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation

City of Hope

Phase 1/2

Los Angeles, California1 trial

IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers

Valkyrie Clinical Trials

Phase 1/2

Sacramento, California1 trial

CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF)

University of California, Davis Comprehensive Cancer Center

Phase 1

Bethesda, Maryland1 trial

Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies

National Institutes of Health Clinical Center

Phase 1/2

Boston, Massachusetts1 trial

IS-free Treg HaploHCT

Dana Farber Cancer Institute

Phase 1

Rochester, New York1 trial

Umbilical Cord Blood Transplantation From Unrelated Donors

Wilmot Cancer Institute

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.